O'Brien on oral tyrosine kinase inhibitors

Dr. Susan O'Brien on kinase inhibitors, interview with Andrew Schoor --

Bottom line:
CAL-101 (now known as GS-1101) and PCI-32765 have shown great results with little myelosuppression. Moving quickly to later phase trials as monotherapy or in combo with chemo and or immunotherapy. Dr O is excited, the FDA is excited as am I if and when my next relapse occurs.....